Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
Humans
Poliovirus Vaccine, Inactivated
/ immunology
Poliomyelitis
/ prevention & control
Infant
Poliovirus Vaccine, Oral
/ immunology
Male
Immunization Schedule
Female
Antibodies, Viral
/ blood
Cross-Sectional Studies
China
Antibodies, Neutralizing
/ blood
Poliovirus
/ immunology
Immunogenicity, Vaccine
Vaccination
IPV
Immunogenicity
Sequential immunization
bOPV
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
received:
14
09
2023
accepted:
08
05
2024
medline:
29
5
2024
pubmed:
29
5
2024
entrez:
28
5
2024
Statut:
epublish
Résumé
To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV). A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60-89 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV + bOPV, 2wIPV + bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose. There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96-384, P<0.05) than the "2IPV + bOPV" group. While the "2IPV + bOPV" group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768-2048, P<0.05)and type 3 (Median:2048, QR: 512-2048, P<0.05) than the IPV-only group. Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.
Sections du résumé
BACKGROUND
BACKGROUND
To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV).
METHODS
METHODS
A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60-89 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV + bOPV, 2wIPV + bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose.
RESULTS
RESULTS
There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96-384, P<0.05) than the "2IPV + bOPV" group. While the "2IPV + bOPV" group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768-2048, P<0.05)and type 3 (Median:2048, QR: 512-2048, P<0.05) than the IPV-only group.
CONCLUSIONS
CONCLUSIONS
Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.
Identifiants
pubmed: 38807038
doi: 10.1186/s12879-024-09389-8
pii: 10.1186/s12879-024-09389-8
doi:
Substances chimiques
Poliovirus Vaccine, Inactivated
0
Poliovirus Vaccine, Oral
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
535Subventions
Organisme : Chongqing Health Commission and Chongqing Science and Technology Commission
ID : 2020FYYX040
Informations de copyright
© 2024. The Author(s).
Références
Estivariz CF et al. Chapter 18: Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases, a.k.a. The Pink Book[M]. 14. Centers for Disease Control and Prevention, United States of America, 2021.
WHO. Poliomyelitis (polio)[EB/OL]. https://www.who.int/health-topics/poliomyelitis#tab=tab_1 .
Global Polio Eradication Initiative. Polio Eradication and Endgame Strategic Plan 2013–2018[EB/OL]. https://polioeradication.org/who-we-are/strategic-plan-2013-2018/ .
Agency Of Disease Control And Prevention. Vaccination work specifications[EB/OL]. (2016-12-29) http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=8033406a995d460f894cb4c0331cb400 .
WHO. Polio vaccines: WHO position paper – June 2022[J]. Wkly Epidemiol Rec. 2022;25(97):277–300.
Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine[J]. Science. 2020;368(6489):401–5.
doi: 10.1126/science.aba1238
pubmed: 32193361
pmcid: 10805349
Cooper LV, Bandyopadhyay AS, Gumede N, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa[J]. Lancet Infect Dis. 2022;22(2):284–94.
doi: 10.1016/S1473-3099(21)00453-9
pubmed: 34648733
pmcid: 8799632
Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral Poliovirus Vaccine Strain[J]. Risk Anal. 2021;41(2):329–48.
doi: 10.1111/risa.13622
pubmed: 33174263
Blake IM, Pons-Salort M, Molodecky NA, et al. Type 2 Poliovirus Detection after global withdrawal of trivalent oral Vaccine[J]. N Engl J Med. 2018;379(9):834–45.
doi: 10.1056/NEJMoa1716677
pubmed: 30157398
pmcid: 5985919
Saleem AF, Yousafzai MT, Mach O, et al. Evaluation of vaccine derived poliovirus type 2 outbreak response options: a randomized controlled trial, Karachi, Pakistan[J]. Vaccine. 2018;36(13):1766–71.
doi: 10.1016/j.vaccine.2018.02.051
pubmed: 29477307
pmcid: 5869272
Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, July 2019-February 2020[J]. MMWR Morb Mortal Wkly Rep. 2020;69(16):489–95.
doi: 10.15585/mmwr.mm6916a1
pubmed: 32324719
pmcid: 7188410
Bigouette JP, Henderson E, Mohamed A, Traoré, et al. Update on vaccine-derived Poliovirus outbreaks - Worldwide, January 2021-December 2022[J]. MMWR Morb Mortal Wkly Rep. 2023;72(14):366–71.
doi: 10.15585/mmwr.mm7214a3
pubmed: 37022974
pmcid: 10078846
Stehling-Ariza T, Wilkinson AL, Diop OM, et al. Surveillance to Track Progress toward Poliomyelitis Eradication-Worldwide, 2021–2022. Morb Mortal Wkly Rep. 2023;72(23):613–20.
doi: 10.15585/mmwr.mm7223a1
Chen Qiang Q, Yuhua L, Hongying, et al. Compare the polio antibody level before and after the conversion of inactivated poliovirus vaccine immunization program[J]. Chin J Microbiol Immunol. 2021;41(07):550–4.
Yang Xiuhui Z, Yong Z, Shuangli, et al. To evaluate the neutralizing antibody of poliovirus in children aged < 12 years of Fujian Province[J]. Chin J Experimental Clin Virol. 2021;35(05):548–54.
Wang Qing Z, Yuanyuan X. Immunogenicity of sequential polio vaccination schedules that use inactivated polio vaccine as the first dose[J]. Chin J Vaccines Immun. 2019;25(04):378–82.
Wen Ning S, Qiru A, Zhijie, et al. Considerations and suggestions for polio vaccination strategies in China[J]. Chin J Vaccines Immunizations. 2018;24(03):349–53.
Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of Poliovirus Antibodies[J]. Methods Mol Biol. 2016;1387:145–76.
doi: 10.1007/978-1-4939-3292-4_8
pubmed: 26983734
Parent DC, I, Merchant AT, Fisher-Hoch S, et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules[J]. Vaccine. 2003;21(15):1710–8.
doi: 10.1016/S0264-410X(02)00523-6
Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J]. N Engl J Med. 2013;368(5):416–24.
doi: 10.1056/NEJMoa1202541
pubmed: 23363495
Geneva: World Health Organization. Considerations for the timing of a single dose of IPV in the routine immunization schedule[EB/OL]. (2014-06-03) https://www.who.int/publications/i/item/WER8901 .
Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of Poliomyelitis in the United States[J]. JAMA. 2004;292(14):1696–701.
doi: 10.1001/jama.292.14.1696
pubmed: 15479934
Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India[J]. Science. 2014;345(6199):922–5.
doi: 10.1126/science.1255006
pubmed: 25146288
pmcid: 10389671
Gaensbauer JT, Gast C, Bandyopadhyay AS, et al. Impact of maternal antibody on the immunogenicity of inactivated Polio Vaccine in infants immunized with bivalent oral Polio Vaccine: implications for the Polio Eradication Endgame[J]. Clin Infect Dis. 2018;67(suppl1):S57–65.
doi: 10.1093/cid/ciy649
pubmed: 30376095
pmcid: 6206111
Asturias EJ, Bandyopadhyay AS, Self S, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in latin American infants: an open-label randomised controlled trial[J]. Lancet. 2016;388(10040):158–69.
doi: 10.1016/S0140-6736(16)00703-0
pubmed: 27212429
Li-na GENG, Kai CHU, Guang-wei SUN, et al. Effectiveness of OPV and the influence of maternal anti-poliovirus antibodies on evaluation of OPV in the Chinese infants[J]. Mod Prev Med. 2017;44(08):1503–6.
Min CUI, De-yu JIANG, Qing HE. Changes in poliovirus neutralizing antibodies among puerperas and infants: a longitudinal study[J]. Chin J Public Health. 2016;32(07):889–92.
Albrecht P, Enterline JC, Boone EJ, et al. Poliovirus and Polio antibody assay in HEp-2 and Vero cell cultures[J]. J Biol Stand. 1983;11(2):91–7.
doi: 10.1016/S0092-1157(83)80031-6
pubmed: 6306012
Xu J, Wang Q, Kuang S, et al. Immunogenicity of sequential poliovirus vaccination schedules with different strains of Poliomyelitis vaccines in Chongqing, China: a cross-sectional survey[J]. Hum Vaccin Immunother. 2021;17(7):2125–31.
doi: 10.1080/21645515.2020.1868269
pubmed: 33759702
pmcid: 8189127